394730-60-0
394730-60-0 structure
- Name: Boceprevir
- Chemical Name: boceprevir
- CAS Number: 394730-60-0
- Molecular Formula: C27H45N5O5
- Molecular Weight: 519.677
- Catalog: Signaling Pathways Anti-infection HCV
- Create Date: 2018-07-03 18:06:18
- Modify Date: 2024-01-04 17:28:09
-
Boceprevir is a novel, potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with Ki of 14 nM in both enzyme assay and EC90 of 350 nM in cell-based replicon assay.
| Name | boceprevir |
|---|---|
| Synonyms |
Boceprevir metabolites
SCH 534128 (1R,2S,5S)-N-(4-Amino-1-cyclobutyl-3,4-dioxo-2-butanyl)-6,6-dimethyl-3-{3-methyl-N-[(2-methyl-2-propanyl)carbamoyl]-L-valyl}-3-azabicyclo[3.1.0]hexane-2-carboxamide Boceprevir Victrelis EBP520 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-, (1R,2S,5S)- [14C]-Boceprevir (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide BOCEPRAVIR |
| Description | Boceprevir is a novel, potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with Ki of 14 nM in both enzyme assay and EC90 of 350 nM in cell-based replicon assay. |
|---|---|
| Related Catalog | |
| Target |
Ki: 14 nM (HCV NS3 protease)[1] |
| In Vitro | In the HCV NS3 protease continuous assay, Boceprevir (SCH 503034) has a potency of 14 nM (Ki) average over a large number of runs. In the 72-h bicistronic subgenomic cell-based replicon assay in HuH-7 cells, the EC50 and EC90 values are determined to be 0.20 µM and 0.35 µM, respectively. Boceprevir is also found to be a very weak inhibitor of HNE (Ki=26 µM) representing a selectivity of 2200[1]. |
| In Vivo | Boceprevir, an HCV Protease Inhibitor for the Treatment of Hepatitis C Virus Infection. The pharmacokinetic profile of Boceprevir is evaluated in several animal species. Following oral administration, Boceprevir is moderately absorbed in rats (10 mg/kg), dogs (3 mg/kg), and monkeys (3 mg/kg). Absorption is relatively rapid in dogs but slower in mice (10 mg/kg), rats, and monkeys, as evidenced by mean absorption times (MAT) ranging from 0.5 to 1.4 h. The AUC is good in dogs and rats, moderate in mouse, and low in monkeys. The absolute oral bioavailability is modest in mouse, rats, and dogs (26-34%) but low in monkeys (4%)[1]. Boceprevir (100 mg/kg, orally) inhibit HCV NS3/4A protease activity in triple-transgenic mice[2]. |
| Animal Admin | Mice[2] Boceprevir is purchased from MedChem Express. To evaluate the effect of Boceprevir, triple-transgenic mice are induced with Doxycycline (Dox) for 10 days (n=5 per group). On the third day after Dox induction, when plasma Gluc activity reaches its peak, the mice are administered either Boceprevir (100 mg/kg) or DMSO via oral gavage twice daily for 7 days. During this period, blood is collected from the caudal vein daily to detect plasma Gluc activity. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Molecular Formula | C27H45N5O5 |
| Molecular Weight | 519.677 |
| Exact Mass | 519.342041 |
| PSA | 150.70000 |
| LogP | 2.05 |
| Index of Refraction | 1.533 |
| Storage condition | -20℃ |
| Hazard Codes | Xi |
|---|
| Precursor 9 | |
|---|---|
| DownStream 0 | |
![(1R,2S,5S)-N-(4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide structure](https://image.chemsrc.com/caspic/096/394735-28-5.png)
![(1R,2S,5S)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid structure](https://image.chemsrc.com/caspic/175/816444-90-3.png)
![2-{[(tert-butoxy)carbonyl]amino}-3-cyclobutylpropanoic acid structure](https://image.chemsrc.com/caspic/106/565456-75-9.png)
![[1-(Cyclobutylmethyl)-2-(MethoxyMethylamino)-2-oxoethyl]-carbamic Acid 1,1-Dimethylethyl Ester structure](https://image.chemsrc.com/caspic/303/394735-18-3.png)
